* reserved prognosis (survival expected by the physician of fewer than three days). * being under immunosuppressive drug treatment. * severe kidney failure (estimated glomerular filtration rate \< 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. * immunosuppressed patients (except when the cause is corticosteroid treatment). * pregnant or lactating women. * patients who plan to become pregnant during the study period or within six months after the end of the study period. * participation in another clinical trial with an experimental drug during the last 30 days. * pathologies that in medical judgment constitute a contraindication to participate in the study.

* reserved prognosis (survival expected by the physician of fewer than three days). * being under immunosuppressive drug treatment. * severe kidney failure (estimated glomerular filtration rate \< 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. * immunosuppressed patients (except when the cause is corticosteroid treatment). * pregnant or lactating women. * patients who plan to become pregnant during the study period or within six months after the end of the study period. * participation in another clinical trial with an experimental drug during the last 30 days. * pathologies that in medical judgment constitute a contraindication to participate in the study.

- reserved prognosis (survival expected by the physician of fewer than three days). - being under immunosuppressive drug treatment. - severe kidney failure (estimated glomerular filtration rate < 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. - immunosuppressed patients (except when the cause is corticosteroid treatment). - pregnant or lactating women. - patients who plan to become pregnant during the study period or within six months after the end of the study period. - participation in another clinical trial with an experimental drug during the last 30 days. - pathologies that in medical judgment constitute a contraindication to participate in the study.

- reserved prognosis (survival expected by the physician of fewer than three days). - being under immunosuppressive drug treatment. - severe kidney failure (estimated glomerular filtration rate < 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. - immunosuppressed patients (except when the cause is corticosteroid treatment). - pregnant or lactating women. - patients who plan to become pregnant during the study period or within six months after the end of the study period. - participation in another clinical trial with an experimental drug during the last 30 days. - pathologies that in medical judgment constitute a contraindication to participate in the study.

cancer diagnosis at any stage and of any type. 2. reserved prognosis (survival expected by the physician of fewer than three days). 3. being under immunosuppressive drug treatment. 4. severe kidney failure (estimated glomerular filtration rate < 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. 5. immunosuppressed patients (except when the cause is corticosteroid treatment). 6. pregnant or lactating women. 7. patients who plan to become pregnant during the study period or within six months after the end of the study period. 8. participation in another clinical trial with an experimental drug during the last 30 days. 9. pathologies that in medical judgment constitute a contraindication to participate in the study. -

cancer diagnosis at any stage and of any type. 2. reserved prognosis (survival expected by the physician of fewer than three days). 3. being under immunosuppressive drug treatment. 4. severe kidney failure (estimated glomerular filtration rate < 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis. 5. immunosuppressed patients (except when the cause is corticosteroid treatment). 6. pregnant or lactating women. 7. patients who plan to become pregnant during the study period or within six months after the end of the study period. 8. participation in another clinical trial with an experimental drug during the last 30 days. 9. pathologies that in medical judgment constitute a contraindication to participate in the study. -